Genomic findings of hypertrophic and dilated cardiomyopathy characterized in a Thai clinical genetics service
Issued Date
2022-09-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-85139240097
Pubmed ID
36166435
Journal Title
PLoS ONE
Volume
17
Issue
9 September
Rights Holder(s)
SCOPUS
Bibliographic Citation
PLoS ONE Vol.17 No.9 September (2022)
Suggested Citation
Trachoo O., Yingchoncharoen T., Ngernsritrakul T., Iemwimangsa N., Panthan B., Klumsathian S., Srisukh S., Mukdadilok A., Phusanti S., Charoenyingwattana A., Chareonsirisuthigul T., Chantratita W., Tangcharoen T. Genomic findings of hypertrophic and dilated cardiomyopathy characterized in a Thai clinical genetics service. PLoS ONE Vol.17 No.9 September (2022). doi:10.1371/journal.pone.0267770 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/86473
Title
Genomic findings of hypertrophic and dilated cardiomyopathy characterized in a Thai clinical genetics service
Author's Affiliation
Other Contributor(s)
Abstract
Hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) are the most common referrals in the Inherited Cardiovascular Condition (ICC) Genetics Service. Several issues must be discussed with patients and their families during the genetic consultation session, including the options for genetic testing and cardiovascular surveillance in family members. We developed an ICC registry and performed next-generation-based DNA sequencing for all patients affected by non-syndromic HCM and idiopathic DCM in our joint specialist genetics service. The target gene sequencing panel relied on the Human Phenotype Ontology with 237 genes for HCM (HP:0001639) and 142 genes for DCM (HP:0001644). All subjects were asked to contact their asymptomatic first-degree relatives for genetic counseling regarding their risks and to initiate cardiovascular surveillance and cascade genetic testing. The study was performed from January 1, 2014, to December 31, 2020, and a total of 62 subjects (31-HCM and 31-DCM) were enrolled. The molecular detection frequency was 48.39% (32.26% pathogenic/likely pathogenic, 16.13% variant of uncertain significance or VUS for HCM, and 25.81% (16.13% pathogenic/likely pathogenic, 9.68% VUS) for DCM. The most prevalent gene associated with HCM was MYBPC3. The others identified in this study included ACTN2, MYL2, MYH7, TNNI3, TPM1, and VCL. Among the DCM subjects, variants were detected in two cases with the TTN nonsense variants, while the others were missense and identified in MYH7, DRSP3, MYBPC3, and SCN5A. Following the echocardiogram surveillance and cascade genetic testing in the asymptomatic first-degree relatives, the detection rate of new cases was 8.82% and 6.25% in relatives of HCM and DCM subjects, respectively. Additionally, a new pre-symptomatic relative belonging to an HCM family was identified, although the genomic finding in the affected case was absent. Thus, ICC service is promising for the national healthcare system, aiming to prevent morbidity and mortality in asymptomatic family members.